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Little research has been published evaluating the effect of non-steroidal antiinflammatory drugs (NSAIDs) on platelet function in dogs. The effects of aspirin and
cyclooxygenase-2 (COX-2) selective NSAIDS on platelet function were evaluated. Eight
dogs received aspirin 10 mg/kg PO every 12 hours for 10 days, and then were randomly
assigned to 4 groups, with each group receiving one of the following PO for 7 days in a
crossover study design: carprofen 2.2 mg/kg every 12 hours, carprofen 4.4 mg/kg every
24 hours, meloxicam 0.2 mg/kg every 24 hours first day then 0.1 mg/kg every 24 hours
for 6 days, or deracoxib 2 mg/kg every 24 hours. PFA-100® platelet function analysis
with collagen/ADP and collagen/EPI cartridges, viscoelastometry, and urine 11-dehydrothromboxane B2 were evaluated. All drugs significantly prolonged PFA-100® closure
times with the collagen/EPI cartridge, but not with collagen/ADP. Urine 11-dehydrothromboxane B2 levels were significantly lower after aspirin but no other drugs.
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CHAPTER I
INTRODUCTION

PLATELET FUNCTION AND HEMOSTASIS
The platelet was first discovered in 1842 by Donné using microscopy, but it wasn’t
until 1885 that Lubnitzky discovered platelets’ primary function in the formation of
hemostatic plugs.1 The platelet was once thought to function only in hemostasis, but it is
now known to be a mediator in processes including inflammation and atherosclerosis.2
Platelets contribute to primary hemostasis in five ways: adhesion, aggregation, secretion,
providing a procoagulant surface, and clot retraction.3
The hemostatic function of platelets could not occur without the cyclooxygenase
enzyme (COX). COX is a catalyst in the production of prostanoids, including
prostaglandins, prostacyclins, and thromboxanes. In platelets, COX oxidizes arachidonic
acid to form prostaglandins (PGG2 and PGH2), which are then isomerized by
thromboxane synthase to form thromboxane A2 (TXA2), the major arachidonic acid
metabolite in platelets. TXA2 is synthesized and released by platelets in response to
activation by conventional agonists, including thrombin and ADP, resulting in enhanced
aggregation and platelet recruitment. In addition, TXA2 in and of itself is also a platelet
activator. When TXA2 synthesis is inhibited, platelet function is altered.
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Two isoforms of COX have been described, COX-1 and COX-2. A newer form,
COX-3, is considered to be a variant of COX-1.4,5 COX-1 is constitutively expressed and
is responsible for prostaglandin regulation in basal physiologic functions, such as normal
platelet activity, gastric cytoprotection, and renal blood flow. It is present in many cells
under basal conditions, including platelets, endothelial cells, mucosal cells of the
gastrointestinal (GI) tract, and renal medullary collecting ducts and interstitium.6 It also
plays a major role in homeostatic activities such as gastric protection, platelet
aggregation, and electrolyte balance in the kidney. COX-2 is induced by various
cytokines and growth factors and is responsible for the production of prostaglandins
involved in the inflammatory process. COX-2 is also present in some cells under basal
conditions, such as macrophages, monocytes, smooth muscle cells, fibroblasts, dendritic
cells, and chondrocytes; as well as some tissues, including kidney and brain.7
The induction of COX-1 in platelets occurs during injury, when damage to blood
vessels results in exposure of the vessel subendothelium. This allows platelets to come
into contact with collagen, von Willebrand factor, and tissue factor, resulting in platelet
adherence and aggregation. This platelet activation initiates the arachidonic acid
pathway, leading to the production of TXA2 by COX, and causing the activation of
additional platelets. The release of ADP, TXA2, and other factors from these activated
platelets results in the aggregation and adhesion of more platelets leading to platelet plug
formation.1

2

NSAIDS AND CYCLOOXYGENASE
Aspirin (acetylsalicylic acid) is a non-selective non-steroidal anti-inflammatory drug
(NSAID) that inhibits both COX-1 and COX-2. Through this COX inhibition, aspirin
has an anti-thrombotic effect by inhibiting TXA2 formation by platelets.6 Because COX-1
plays a role in both normal platelet function and prostaglandin-mediated cytoprotection
of the gastrointestinal mucosa, inhibition of COX-1 can lead to gastrointestinal ulceration
and bleeding. In the past decade, much research has been undertaken to develop NSAIDS
that are specifically COX-2 selective in an effort to maintain the analgesic and antiinflammatory properties of the drug while minimizing systemic side-effects related to
inhibition of COX-1.8,9,10
Theoretically, COX-2 selective NSAIDS should have no effect on platelet function,
as platelets have been thought to be the only cells in the dog that exclusively express
COX-1.11,12 However, recent research has shown that so-called COX-2 selective NSAIDS
are not truly selective for only COX-2, and that selectivity may decrease as the dose
increases.8,13 The selectivity of an NSAID is now based on drug concentrations at which
enzyme activity is inhibited by 50% (inhibitory concentration [IC50]) that are calculated
and described as a ratio of COX-1:COX-2,11 since none appear to be completely COX-2
selective.9 NSAIDS with a ratio of >1 are more COX-2 selective and generally cause
fewer side effects when used clinically.12,14,15,16 Therefore, platelet function may, in fact,
be altered to varying degrees by all NSAIDS, even those thought to be COX-2 selective.
This would help explain the continued incidence of complications (i.e., anorexia,
vomiting, nausea, and gastrointestinal ulceration) seen clinically in dogs treated with
more selective NSAIDS. In dogs, carprofen, deraxocib, meloxicam, and etodolac have
3

been shown to inhibit COX-1 less severely than previous non-selective NSAIDS, as
determined by the continued synthesis of gastric PGE1 and PGE2 and the continued
production of thromboxane B2 (TXB2 – a stable metabolite of TXA2) by platelets.9,10,17,18
However, another study reported a decrease in TXB2 concentrations in pyloric mucosa
after treatment with carprofen.19

EFFECTS OF NSAIDS ON PLATELET FUNCTION AND HEMOSTASIS
The effects and complications of NSAIDS are so concerning because they are very
commonly used in both human and veterinary medicine for treatment of acute and
chronic pain and inflammation. Reported systemic adverse drug reactions associated with
NSAIDS comprise the largest database within the United States Food and Drug
Administration’s Center for Veterinary Medicine files, and most of these reactions were
reported with the use of COX-2 selective NSAIDS.20 Although reports conclude that
there are fewer side effects associated with COX-2 selective NSAIDS, as compared to
non-selective NSAIDS, severe systemic side effects can still occur.13,21
Scientists have investigated the effects of COX-2 selective NSAIDS on bleeding in
dogs, with conflicting results. Carprofen is one of the most commonly used COX-2
selective NSAIDS in veterinary medicine, and conflicting reports of its effect on bleeding
have been described.21,22,23,24,25,26 In a recent study significant decreases in platelet
aggregation and clot formation were reported in dogs treated with carporfen.27 Another
study, evaluating the effects of carprofen in healthy Labrador retrievers, demonstrated a
decrease in platelet aggregation and delayed onset of aggregation, with no differences
detected in buccal mucosal bleeding time (BMBT) or hematocrit.22 A report comparing
4

the effects of several COX-2 selective NSAIDS in dogs found that bleeding time was
increased after 1 month and 3 months of caroprofen administration.21 However, in
another report, dogs receiving carprofen after suffering a fracture had no changes or
abnormalities in bleeding time, platelet aggregation, hematocrit, or platelet count.26
Other COX-2 selective NSAIDS used in dogs have also been evaluated. Grisneaux
reported that bleeding time was prolonged in dogs administered ketoprofen as compared
to carprofen or saline (control) prior to orthopedic surgery.23 Another study demonstrated
that flunixin, ketoprofen, and meloxicam all increased clotting times, and bleeding time
was increased after 7 days of treatment.21 However, the perioperative administration of
meloxicam or ketoprofen was found to have no affect on BMBT.28,29.30,31
Veterinary medicine is not the only field investigating NSAIDS. The effects of
NSAIDS on platelet function, and particularly the potential for intraoperative bleeding, is
a concern in human medicine as well. NSAIDS are used with caution in people
undergoing tonsillectomy due to the potential for intraoperative blood loss, postoperative
bleeding, and reoperation because of bleeding.32 The administration of a non-selective
NSAID 2 weeks prior to total hip replacement in humans has resulted in significantly
increased peri-operative blood loss.33 A study of human patients on various COX
inhibitors and undergoing total knee replacement surgery positively correlated PFA-100®
EPI closure time with both postoperative drain output for the first 24 hours and the
surgeon’s rating of the difficulty of achieving hemostasis intraoperatively.34 The PFA100® is a commercial machine used to evaluate platelet function via exposure of platelets
to agonists, mimicking platelet activation in response to contact with vessel
subendothelium after trauma.
5

Potential complications of NSAID usage
Alterations in platelet function not only affect intraoperative bleeding, they also
influence other side effects of NSAIDS, including changes in gastric mucosal protection,
potentially resulting in bleeding gastrointestinal ulcers. Gastric ulcers have been
documented after the administration of NSAIDS, and the incidence is increased if they
are used in conjunction with steroids.19,21,35,36 Just as with studies regarding NSAIDS
effect on bleeding, results of their effects on the gastrointestinal system are conflicting.
Aspirin has been found to decrease COX-1 and COX-2 concentrations in both pyloric
and duodenal mucosa, which is to be expected as it is non-selective. However, in the
same study, carprofen, a COX-2 selective NSAID, was also found to decrease total
prostaglandin and TXB2 concentrations in the pyloric mucosa as compared to
deracoxib.19 The administration of deracoxib or carprofen to healthy dogs for 5 days
resulted in no significant gastroduodenal ulcers as evaluated endoscopically.18 However,
in another study, carprofen, etodolac, ketoprofen, meloxicam, and flunixin were
administered to dogs for 90 days, and gastric lesions were recongnized endoscopically in
all dogs .21 In this study, carprofen administration was shown to cause the fewest
gastrointestinal effects, followed by meloxicam, etodolac, flunixin, and ketoprofen.
The effects of long-term administration of COX-2 selective NSAIDS warrant
continued investigation, as more drugs are being approved for chronic treatment of
osteoarthritis. Previous studies have evaluated NSAIDS effects on the gastric mucosa, but
also in the synovial fluid. Administration of firocoxib and meloxicam to osteoarthritic
dogs has been shown to decrease concentrations of PGE2 in synovial fluid in a similar
6

manner in which they decrease plasma PGE2 concentrations,17 confirming their benefit in
treating joint inflammation and arthritis. A study of the effects of administering
carprofen and deracoxib to dogs with chronic osteoarthritis reported simliar results,
including decreased PGE2 concentrations in blood and synovial fluid and no suppression
of TXB2 blood concentrations or gastric PGE1 synthesis. These findings confirm the
COX-2 selectivity of these drugs.10

Aspirin resistance
Aspirin is the most extensively used and researched antiplatelet drug in human
medicine due to its benefit in cardiovascular disease. The antiplatelet function of aspirin
is via irreversible acetylation of Ser-529 in COX-1 and Ser-516 in COX-2, resulting in
blockage of TXA2 synthesis. “Aspirin resistance” is a term used in human medicine to
refer to patients who have thrombotic events despite aspirin treatment. The term is also
applicable if a prolongation in bleeding time is detected or if the expected inhibition of
platelet activation or TXA2 synthesis is not achieved.2,37 Research has confirmed that
humans have a variable response to aspirin therapy.38,39 This variable response is thought
to result from differences in prostaglandin production whereby COX-2 restores the ability
of platelets to produce TXA2 in some patients,38,40,41 although additional theories exist.
Aspirin resistance lacks uniformity, and previous studies estimate that 8-45% of the
human population are aspirin resistant.42,43,44,45 It was also determined that the optimal
dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists
(i.e. arachidonic acid) is subject to great interindividual variability, the preferred tests for
detecting aspirin resistance in vitro are subject to debate, and the mechanisms by which
7

some patients are resistant to aspirin remain to be determined. Clinical vs. biochemical
aspirin resistance in humans was investigated by Kour, et al46 and suspected mechanisms
responsible for resistance include reduced accessibility of aspirin to receptor sites due to
concomitant intake of other NSAIDS; genetic polymorphism of enzymes like COX-1,
COX-2, or thromboxane A2 synthase; increased reactivity of platelets towards other
aggregating factors; increased rate of entry of new platelets into the circulation; alternate
pathways of thromboxane synthesis; and poor patient compliance. Aspirin resistance has
also been associated with reticulated platelets,39 which are young platelets that contain
mRNA. In addition, it has been discovered that variation in response to aspirin may be
associated with time in humans, as Dalby, et al47 found a diurnal increase in closure time
of 30% from 8:30am to 5pm with both collagen/epinephrine (Epi) and collagen/ADP
PFA-100 cartridges. However, a more recent study48 found a less variable response to
aspirin. In this study, repeated optical arachidonic acid-induced platelet aggregometry
was used on 289 patients with stable congestive heart diseases and all the subjects
demonstrated ability to respond normally to aspirin in low doses. The authors of this
study concluded that pharmacodynamic aspirin resistance is rare.
Very little research in veterinary medicine has been performed regarding aspirin
resistance. One published report on the effects of aspirin on platelet function in dogs
demonstrated a variable response within and amongst breeds.49 However, whether dogs,
like humans, may be “responders”, “semiresponders”, or “nonresponders” to aspirin
therapy remains in question.
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CHAPTER II
EVALUATION OF THE EFFECTS OF COX-2 SELECTIVE NSAIDS ON
PLATELET FUNCTION

INTRODUCTION
Nonsteroidal anti-inflammatory drugs are commonly administered to dogs for the
control of pain and inflammation associated with osteoarthritis and other chronic and
acute inflammatory conditions. In addition, nonsteroidal anti-inflammatory drugs
(NSAIDs) are frequently used peri-operatively to reduce pain and inflammation and
minimize post-operative opioid requirements, and thus speed recoveries and shorten
hospital stays. The anti-inflammatory and analgesic effects of all NSAIDs result from the
inhibition of COX, an enzyme that converts arachidonic acid to a number of different
prostanoids including the prostaglandins, the prostacyclins, and thromboxane. There are
two well described isoforms of this enzyme, COX-1 and COX-2, although more recently
a third possible isoform or splice variant, COX-3, has been described. COX-1 is
constitutively expressed and is responsible for prostaglandin regulation in basal
physiologic functions, including normal platelet activity, gastric cytoprotection, and renal
blood flow.13,50 COX-2 is traditionally considered to be inducible and responsible for
producing the prostaglandins that are involved in the inflammatory process. 13,50
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Aspirin (acetylsalicylic acid) is a non-selective NSAID that irreversibly binds to and
affects the function of both COX-1 and COX-2, and impairs platelet function by
inhibiting thromboxane A2 (TXA2) formation by platelets.6 TXA2 is synthesized and
released by activated platelets resulting in vasoconstriction, further platelet activation,
and enhanced platelet aggregation. Inhibition of COX-1 mediated TXA2 synthesis leads
to decreased platelet function. Inhibition of COX-1 also reduces prostaglandin-mediated
cytoprotection of the gastrointestinal mucosa, potentially leading to gastrointestinal
ulceration and bleeding. In the past decade, much research has been devoted to the
development of COX-2 selective NSAIDs that maintain analgesic and anti-inflammatory
effects while minimizing unwanted side-effects thought to result primarily from COX-1
inhibition such as gastrointestinal ulceration, renal damage and susceptibility to
bleeding.8,9,10
Platelets, both in the dog and in man, have historically been described as cells that
exclusively express COX-1. Therefore, it was assumed that the newer COX-2 selective
NSAIDs should have no direct effect on platelet function.11,12 Recent research, however,
has shown that many ‘COX-2 selective NSAIDs’ are not purely selective for COX-2,
and that selectivity may decrease as drug dose increases.8,13 All NSAIDs, even those
marketed as COX-2 selective, may therefore have the potential to inhibit COX-1 and
thereby decrease platelet function.
Administration of NSAIDs before surgery has the beneficial effects of reducing
inflammation at the surgical site, minimizing resultant peripheral and central
amplification of nociceptive input, and decreasing pain after surgery.29 Undesirable
NSAID-associated decreases in platelet function, however, have the potential to
10

contribute to excessive peri-operative hemorrhage, leading to longer surgical and
anesthetic times and an increased risk of intra- and post-operative complications. In
theory, compared to non-selective NSAIDs, the more COX-2 selective NSAIDs would be
expected to have far less effect on platelet function and thus should not lead to unwanted
peri-operative hemorrhage. The effects of the newer, more selective NSAIDs on canine
primary hemostasis, however, have not as yet been comprehensively evaluated using
appropriate methodologies.
The goal of our study was to characterize changes in platelet function associated with
the administration of standard anti-inflammatory doses of aspirin and other veterinaryapproved NSAIDs of varying COX-2 selectivity in dogs. Our hypotheses were that
aspirin at standard anti-inflammatory doses would predictably interfere with platelet
function, and that the other more COX-2 selective NSAIDs, while less potent in their
effects on platelets, would still cause detectable alterations in platelet function.

MATERIALS AND METHODS
Eight female intact purpose-bred adult Walker Hound dogs were used for the study.
Normal health status was established based on physical examination and baseline testing
including a complete blood count, serum chemistry, urinalysis, BMBT, prothrombin
time, partial thromboplastin time, von Willebrand factor levels, heartworm testing and
titers for rickettsial diseases and Babesia species. No vaccines or medications were
administered to the dogs for at least one month prior to initiation of the project.
Baseline samples were obtained for platelet function analysis using a point-ofcare platelet function analyzera (Siemens PFA-100®), viscoelastometryb (Sienco
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SonoClot®), and measurement of urine 11-dTXB2c (Luminex® 11-dehydro Thromboxane
B2 Kit). Venous blood was collected from the jugular veins via a 20-gauge vacutainer
needle directly into glass tubes containing either 3.8% sodium citrate or
ethylenediaminetetraacetic acid (EDTA). Venipuncture was performed by alternating
between both jugular veins. An automated hematologic analyzerd (Abbott Cell-Dyn®
3700) was used to determine an accurate platelet count and packed cell volume (PCV) on
each sample. Urine was collected via cystocentesis using a 22 gauge needle. All urine
samples were batched and stored at -80oC until analysis.

Platelet Function Analysis (PFA-100®)
The PFA-100® device was used according to the manufacturer’s instructions, and
has previously been described and evaluated in dogs.51,52 The PFA-100® is a bench-top
analyzer that measures the time needed to form a platelet plug in an environment
designed to mimic the naturally-occurring situation in blood vessels. The PFA-100®
moves whole blood at high shear forces across a membrane aperture during exposure to
platelet agonists, thereby mimicking damaged subendothelium in a blood vessel. The
PFA-100® evaluates primary hemostasis as a whole by recording closure time (CT), the
time needed to close the aperture by forming a platelet plug after platelet activation.
Sodium citrate anticoagulated blood at a 9:1 blood-to-citrate ratio was used. Samples
were analyzed within 30 minutes of collection, and kept at room temperature until
analysis. For each sample, 800 µl of citrated blood was deposited in a test cartridge,
which contained a biologically active membrane coated with either collagen and
adenosine diphosphate (collagen/ADP cartridge)e or collagen and epinephrine
12

(collagen/EPI cartridge)f. After a 3-minute incubation period at 37°C, the blood sample
was aspirated through an aperture in contact with the coated membrane, and the time
until occlusion of the aperture (closure time) was recorded.

Viscoelastometry (SonoClot®)
The SonoClot® device was used according to the manufacturer’s instructions. The
SonoClot® uses a viscoelastometric system to detect mechanical changes that occur
within a whole blood sample as it clots, and provides information on many aspects of the
hemostatic process, including coagulation, fibrin gel formation, and clot retraction. The
SonoClot® contains a tubular probe that oscillates up and down within a blood sample,
with detection circuitry that senses the resistance to motion that the probe encounters as
the sample clots and generates an analog electronic signal which is processed by a
microcomputer and reported as a clot signal or, graphically, as a SonoClot® signature.
Clotting was triggered using the SonACT® Kitg, which is a celite-activated whole blood
clotting time test designed for use with the SonoClot®. Results calculated by the
SonoClot® and the Signature Viewer Programh from the resultant clot signal included the
activated clotting time (ACT; or the time until onset of the first detectable clot) in
seconds, the clot rate (CR; or the slope of the SonoClot® signature during initial fibrin gel
formation) in clot signal units per minute, the peak amplitude of the SonoClot® signature
(AMP) in clot signal units, and the time to peak amplitude (TP) in minutes. The
SonoClot® Signature Viewer Program utilizes AMP and TP to calculate ‘platelet
function’ (PF), an index which is claimed by the manufacturer to reflect the role of
platelets in clot formation. Sodium citrate anticoagulated blood at a 9:1 blood-to-citrate
13

ratio was used. Samples were analyzed within 30 minutes of collection, and kept at room
temperature until analysis. Each sample was tested in duplicate.

Urine 11-Dehydro-Thromboxane B2
A commercial competitive enzyme immunoassay kit validated for analysis of
canine urine for 11-dTXB2 was used to measure thromboxane (Cayman Chemical
Company). Samples were analyzed according to the manufacturer’s instructions. Urine
samples were serially diluted with the manufacturer’s assay buffer based on the original
specific gravity in order to have the specific gravity of the sample within the working
range of the instrument, which was isosthenuric. All samples were analyzed in duplicate,
and results were reported in pictograms per milliliter of urine (a correction factor was
applied to allow for the effects of sample dilution). Briefly, a 96-well Luminex® plate
was prepared by adding 100 µl of the diluted sample to the appropriate well, followed by
the addition of 11-dTBX2 Phycoerythrin Tracer and 11-dTBX2 XMAPR® Beads. The
plate was placed on an orbital shaker and incubated in the dark at room temperature for
four hours prior to analysis. Urine 11-dTBX2 concentration was normalized to the
individual’s urine creatininei by determining the 11-dTBX2 to creatinine ratio using the
diluted urine.

Buccal Mucosal Bleeding Time
A commercially available device (Triplett®j or HemoHeel®k) was used to perform a
BMBT on the everted lip of all dogs on the last day of drug administration for all drugs
according to a previously described technique.53 The two devices function similarly,
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creating a standardized 1 mm deep incision; the incision length made with the Triplett® is
5-6 mm and with the HemoHeel® is 2.5 mm. Filter paper was used to blot 1-2 mm from
the incision until cessation of bleeding.

Study Design
This study was designed in accordance with the Policy on the Humane Care and Use
of Laboratory Animals and was approved by the Mississippi State University Institutional
Animal Care and Use Committee. All dogs were administered aspirinl at 10 mg/kg PO
every 12 hours for 10 days in order to establish the effects of a standard non-selective
NSAID on hemostatic test results. The dogs were then randomly assigned to one of four
groups (2 dogs/group) and treated for 7 days with one of the following regimens with
each group rotating through all drug regimens in a crossover design: carprofenm 2.2
mg/kg PO every 12 hours, carprofenm 4.4 mg/kg PO every 24 hours, meloxicamn 0.2
mg/kg PO the first day then 0.1 mg/kg PO every 24 hours, or deracoxibo 2 mg/kg PO
every 24 hours. Drug doses were based on manufacturer’s recommendations. A 14 day
washout period was established between each drug. During drug administration, blood
was obtained for PFA-100® analysis using collagen/EPI cartridges on days 1, 2, 3, 5, and
7. On day 7, blood was collected for PCV, platelet count, viscoelastometry, and PFA100® analysis using collagen/ADP cartridges. During the washout period, PFA-100®
analysis using collagen/EPI cartridges was performed every other day until measurements
within 10% of each individual dog’s normal baseline were obtained on two consecutive
occasions. On Day 14 of the washout period, blood samples were obtained for PCV,
platelet count, PFA-100® analysis using collagen/ADP cartridges and viscoelastometry.
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Urine was collected for 11-dTXB2 analysis on Day 7 of administration of each drug.
BMBT was evaluated at baseline and on the last day of drug administration for each drug,
including aspirin.

Statistical Analysis
Results of PFA-100® analysis, urine 11-dTBX2, and viscoelastometry in dogs
treated by aspirin were individually assessed by analysis of variance (ANOVA) using the
GLIMMIX procedure in SAS for Windows version 9.2p followed by separation of means
using least significant difference. Sample time was included in the model as a fixed
effect. The identity of the dogs was used in RANDOM and RANDOM_RESIDUAL
statements to account for the repeated measures of dogs over time. For the PFA-100®
analysis using collagen/EPI cartridge outcomes, which were measured at five time points,
a first order autoregressive covariance structure was used. An unstructured covariance
structure was used for PFA-100® analysis using collagen/ADP cartridges, urine 11dTXB2, and viscoelastometry (ACT, CR, PF) outcomes, which each had only two sample
times.
The effects of carprofen (both dosing regimens), deracoxib, and meloxicam on PFA100®, viscoelastometry, platelet count, and urine 11-dTXB2 results were assessed by
analysis of variance using the GLIMMIX procedure in SAS for Windows version 9.2
followed by separation of means using least significant difference. Drug, rotation,
sample time, and the drug*sample time interaction were included in the models as fixed
effects. In addition, dummy variables were created to account for the drug a dog had
been treated with in the prior rotation. The identity of dog within rotation was used in
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RANDOM and RANDOM_RESIDUAL statements to account for the repeated measures
of dogs over time. For the PFA-100® analysis using collagen/EPI cartridges outcomes,
which were measured at six time points, a first order autoregressive covariance structure
was used. An unstructured covariance structure was used for the other dependent
variables, which each had only two sample times. All analyses tested differences in drug,
sample, time, rotation, and drug*sample time interaction.
A P value of less than 0.05 was considered to be significant for all analyses.

RESULTS
Eight dogs (intact females ranging in age from 1-6 years [median, 5.21 years]) were
included in the study. All dogs were Walker Coonhounds. Weights ranged from 20.5 to
24.2 kg (median, 22.3 kg). All dogs completed the study, with one dog receiving oral
sucralfateq 1 g PO q8h for 5 days due to hematochezia observed during the washout
period after receiving meloxicam. No other adverse effects were observed.
After accounting for the dogs’ individual weights, the mean administered dosages of
drugs were aspirin, 10.62 ± a standard deviation of 0.610 mg/kg, PO, q 12 h; carprofen,
2.18 ± 0.124 mg/kg, PO, q 12 h; carprofen, 4.36 ± 0.247 mg/kg, PO, q 24 h; meloxicam,
0.19 ± 0.013 mg/kg, PO, first dose, then 0.097 ± 0.006 mg/kg, PO q 24 h; and deracoxib,
2.18 ± 0.122 mg/kg, PO, q 24 h.

Platelet Function Analysis (PFA-100®)
Pretreatment (baseline) closure times using collagen/EPI cartridges were not significantly
different among groups for any drug. Collagen/EPI cartridge CTs were significantly
17

longer (P = <0.0001) than baseline values at all time points during treatment with aspirin,
but there was no significant difference in closure time among any time points after
baseline (Figure 1). Collagen/EPI cartridge CTs were significantly longer than baseline
values (P = <0.0001) at all time points during treatment with carprofen 2.2 mg/kg twice
daily (Figure 2), carprofen 4.4 mg/kg once daily (Figure 3), meloxicam (Figure 4), and
deracoxib (Figure 5), but there was no significant difference in closure time among any
time points after baseline, and there was no significant difference in closure time between
the four drug regimens. When individual dog responses to various NSAIDs are
evaluated, however, only aspirin caused consistently prolonged CTs in all dogs at all time
points during drug administration (Figure 6). In contrast, 6 of 8 dogs returned to baseline
CTs (defined as within 10% of their baseline value) at least once (range 1-3 times) while
receiving carprofen 2.2mg/kg twice daily (Figure 7); 5 of 8 returned to baseline CTs
twice while receiving carprofen 4.4mg/kg once daily (Figure 8); 3 of 8 returned to
baseline CTs at least once (range 1-3 times) while receiving meloxicam (Figure 9); and 6
of 8 returned to baseline CTs at least once (range 1-4) times while receiving deracoxib
(Figure 10). During the washout period, the average number of days until return to
normal CTs using the collagen/EPI cartridges was 5.6 days for aspirin, 11.6 days for
carprofen at 2.2mg/kg twice daily, 10.6 days for carprofen at 4.4mg/kg once daily, 11
days for meloxicam, and 10.6 days for deracoxib.
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Figure 1 – Mean PFA-100 closure time with collagen/epinephrine cartridge over time for
8 dogs after treatment with aspirin
Mean PFA-100 closure time with collagen/epinephrine cartridge (+/- S. E)
over time for 8 dogs after treatment with aspirin (10 mg/kg PO every 12
hours for 10 days).
* significantly increased over baseline value (p>0.05).
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Figure 2 – Mean PFA-100 closure time with collagen/epinephrine cartridge over time of
8 healthy dogs after treatment with caprofen 2.2 mg/kg twice daily
Mean PFA-100 closure time with collagen/epinephrine cartridge (+/- S. E)
over time of 8 healthy dogs after treatment with carprofen (2.2 mg/kg PO
every 12 hours for 7 days).
* significantly increased over baseline value (p>0.05).
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Figure 3 – Mean PFA-100 closure time with collagen/epinephrine cartridge over time of
8 healthy dogs after treatment with caprofen 4.4 mg/kg once daily
Mean PFA-100 closure time with collagen/epinephrine cartridge (+/- S. E)
over time of 8 healthy dogs after treatment with carprofen (4.4 mg/kg PO
every 24 hours for 7 days).
* significantly increased over baseline value (p>0.05)
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Figure 4 – Mean PFA-100 closure time with collagen/epinephrine cartridge over time of
8 healthy dogs after treatment with meloxicam
Mean PFA-100 closure time with collagen/epinephrine cartridge (+/- S. E)
over time of 8 healthy dogs after treatment with meloxicam (0.2 mg/kg first
day then 0.1 mg/kg PO every 24 hours for 6 days).
* significantly increased over baseline value (p>0.05).
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Figure 5 – Mean PFA-100 closure time with collagen/epinephrine cartridge over time of
8 healthy dogs after treatment with deracoxib
Mean PFA-100 closure time with collagen/epinephrine cartridge (+/- S. E)
over time of 8 healthy dogs after treatment with deracoxib (2 mg/kg PO every
24 hours).
* significantly increased over baseline value (p>0.05).
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Figure 6 – Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with aspirin.
Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with aspirin (10 mg/kg PO every 12 hours).
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Figure 7 – Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with carprofen 2.2 mg/kg twice daily.
Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with carprofen (2.2 mg/kg PO every 12 hours for
7 days).
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Figure 8 – Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with carprofen 4.4 mg/kg once daily.
Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with carprofen (4.4 mg/kg PO every 24 hours for
7 days).

26

350
300
250

Dog 1
Dog 2

200

Dog 3
Dog 4

150

Dog 5
Dog 6
Dog 7

100

Dog 8
50
0
Baseline

Day 1

Day 2

Day 3

Day 5

Day 7

Figure 9 – Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with meloxicam.
Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with meloxicam (0.2 mg/kg first day then 0.1
mg/kg PO every 24 hours for 6 days).
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Figure 10 – Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with deracoxib
Results of analysis with PFA-100 with collagen/epinephrine cartridge of 8
healthy dogs after treatment with deracoxib (2 mg/kg PO every 24 hours).

For collagen/ADP cartridge CTs, there was no significant difference seen with
aspirin administration between baseline and Day 10 results, nor for the more COX-2
selective NSAIDs evaluated was there any significant difference noted between any drug
or between baseline and Day 7 for any drug (Figure 11).
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Figure 11 – Mean PFA-100 closure time with collagen/ADP cartridge over time of 8
healthy dogs after treatment with aspirin, carprofen, meloxicam, and
deracoxib
Mean PFA-100 closure time with collagen/ADP cartridge (+/- S. E) over
time of 8 healthy dogs after treatment with aspirin, carprofen, meloxicam,
and deracoxib (aspirin 10 mg/kg PO every 12 hours for 10 days, carprofen
2.2 mg/kg PO every 12 hours for 7 days, carprofen 4.4 mg/kg PO every 24
hours for 7 days, meloxicam 0.2 mg/kg first day then 0.1 mg/kg PO every 24
hours for 6 days, and deracoxib 2 mg/kg PO every 24 hours for 7 days).
No significant difference found.
Viscoelastometry (SonoClot®)
Viscoelastometry was performed at baseline and on the last day of drug
administration for all drugs. A significant difference in ACT results was seen with drug
but not time: carprofen 4.4mg/kg once daily had a longer ACT than carprofen 2.2mg/kg
twice daily (P = 0.013), meloxicam (P = 0.046), and deracoxib (P = 0.019) (Figure 12).
A significant difference in CR results was seen with drug but not time: carprofen
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4.4mg/kg once (P = 0.027) and 2.2mg/kg twice daily (0.004) had a faster CR than did
deracoxib (Figure 13). No significant differences in PF were seen between drugs or over
time.
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Figure 12 – Mean activated clotting time (ACT) with viscoelastometry over time of 8
healthy dogs after treatment with aspirin, carprofen, meloxicam, and
deracoxib
Mean activated clotting time (ACT) with viscoelastometry (+/- S. E) over
time of 8 healthy dogs after treatment with aspirin, carprofen, meloxicam,
and deracoxib (aspirin 10 mg/kg PO every 12 hours for 10 days, carprofen
2.2 mg/kg PO every 12 hours for 7 days, carprofen 4.4 mg/kg PO every 24
hours for 7 days, meloxicam 0.2 mg/kg first day then 0.1 mg/kg PO every
24 hours for 6 days, and deracoxib 2 mg/kg PO every 24 hours for 7 days).
* significantly increased over baseline value (p>0.05)
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Figure 13 – Mean clot rate with viscoelastometry over time of 8 healthy dogs after
treatment with aspirin, carprofen, meloxicam, and deracoxib
Mean clot rate with viscoelastometry (+/- S. E) over time of 8 healthy dogs
after treatment with aspirin, carprofen, meloxicam, and deracoxib (aspirin 10
mg/kg PO every 12 hours for 10 days, carprofen 2.2 mg/kg PO every 12 h
ours for 7 days, carprofen 4.4 mg/kg PO every 24 hours for 7 days,
meloxicam 0.2 mg/kg first day then 0.1 mg/kg PO every 24 hours for 6 days,
and deracoxib 2 mg/kg PO every 24 hours for 7 days).
* significantly decreased from baseline value (p>0.05)

Urine 11-Dehydro-Thromboxane B2
Urine 11-dTBX2 levels decreased significantly during aspirin administration from
baseline to the last day of drug administration (day 10) (P = 0.014). There was no
significant difference in urine 11-dTBX2 levels among any other drugs or time points,
although 11-dTBX2 levels dropped below baseline levels for all drugs (Figure 14).
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Figure 14 – Mean urine 11-dehydro-thromboxane B2 (11-dTXB2) levels after treatment
with aspirin, carprofen, meloxicam, and deracoxib
Mean urine 11-dehydro-thromboxane B2 (11-dTXB2) levels after treatment
with aspirin, carprofen, meloxicam, and deracoxib (aspirin 10 mg/kg PO
every 12 hours for 10 days, carprofen 2.2 mg/kg PO every 12 hours for 7
days, carprofen 4.4 mg/kg PO every 24 hours for 7 days, meloxicam 0.2
mg/kg first day then 0.1 mg/kg PO every 24 hours for 6 days, and deracoxib
2 mg/kg PO every 24 hours for 7 days).
* significantly decreased from baseline value (p>0.05).

Other Testing
No significant differences were seen in platelet count or PCV with regards to time or
drug for any of the drugs evaluated. Due to a laboratory error, the baseline measurements
for PCV and platelet count for the second rotation in the more COX-2 selective NSAIDs
crossover trial (rotation B) were unavailable, so a baseline measurement was created by
averaging the baseline measurements for the other three rotations (rotations A, C and D).
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BMBT remained within normal limits (less than 3 minutes)53 for all dogs at all time
points.

DISCUSSION
Non-selective NSAIDs such as aspirin have long been considered to be contributing
risk factors for peri-operative hemorrhage in both humans and dogs due to their effects on
platelet function.21,23,33,34,53 One of the perceived benefits of the newer more COX-2
selective NSAIDs is that they would be expected to have less effect on platelet function
than drugs like aspirin. The primary purpose of our study was therefore to determine the
effects of the newer more COX-2 selective NSAIDs on a comprehensive panel of tests of
platelet function in the dog.
The clear and consistent response to aspirin among dogs in our study group as
measured by PFA-100® (collagen/EPI) (Figure 1) and urinary 11-dTXB2 (Figure 14) was
both statistically significant and visually dramatic. Standard doses of the newer NSAIDs
appear to have much the same effect, but to a lesser extent and with much wider
individual dog variability.
All of the newer NSAIDs evaluated do appear to have a measurable effect on platelet
function. As measured by PFA-100® (collagen/EPI), closure time was significantly
prolonged from baseline to all other time points for all drugs with no significant
difference between time points beyond baseline. Yet to be determined is whether this
altered platelet function correlates with intra-operative hemorrhage. In human medicine,
the finding that NSAIDs affect laboratory measures of platelet function has lead to the
recommendation that, whenever possible, NSAIDs should be avoided prior to surgeries
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where significant hemorrhage is expected.32,33,34 In dogs, a significant but weak
association has been made between a prolonged BMBT and blood loss intraoperatively,54
and aspirin has been reported to significantly prolong BMBT.53 Interestingly, in our
study, for all dogs during administration of all drugs (including aspirin), the BMBT was
within the normal range, however this is consistent with a number of other previous
studies.22,29,31 Based on our results, while we cannot conclude that the newer NSAIDs will
predispose to clinical bleeding, we have clearly demonstrated that they do have an effect
on laboratory measures of platelet function, and therefore should be used with caution in
surgical patients that are at risk for bleeding.
While our study is very similar in overall design to two recent studies by Blois and
others55 and by Brainard and others,27 our results and general conclusions are very
different. Blois and others55 evaluated the effects of one week of oral aspirin, carprofen,
deracoxib, and meloxicam on platelet function in 10 healthy dogs using a comprehensive
panel of tests including plasma thromboxane B2 (TXB2) and 6-keto prostaglandin F1α
(PGF1α), platelet aggregometry using ADP and platelet-activating factor as agonists, and
platelet function analysis using the PFA-100®, and concluded that these NSAIDS had
minimal effect on platelet function. Interestingly, Blois and others55 reported that oral
aspirin at the same dose used in our study had no detectable effect on platelet function,
which is in contrast to the findings in our study which documented a consistent and
marked decrease in several measures of platelet function. We believe that these differing
results are due to differences in the techniques used for measuring platelet function in the
two studies: in particular, differences in the PFA-100® and thromboxane assays used.
Firstly, Blois and others55 measured platelet function with the PFA-100® using the
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collagen/ADP cartridge, whereas our study predominantly utilized the PFA-100®
collagen/EPI cartridge. In people, Kundu and others51 describe the use of the two
different PFA-100® cartridges to allow differentiation of aspirin-induced platelet
dysfunction from other congenital and acquired platelet function defects. If platelet
dysfunction is due to aspirin, then PFA-100® collagen/EPI measurements will tend to be
abnormal while collagen/ADP measurements will remain within the normal range,
because the collagen/ADP cartridge appears to be less sensitive to aspirin-induced
platelet dysfunction and therefore selects for more severe platelet disorders. Similarly, in
dogs, Nielsen and others49 found that administration of aspirin prolonged PFA-100®
closure times when using collagen/EPI cartridges, but not when collagen/ADP cartridges
were utilized. Our study results are very comparable to those of Neilsen and others49, and
strongly suggest that, in dogs as in people, prolongation of PFA-100® closure time
utilizing the collagen/EPI cartridge is a sensitive indicator of NSAID-induced platelet
dysfunction, whereas in contrast the collagen/ADP cartridge appears to be a very
insensitive indicator. Secondly, Blois and others55 measured the effects of NSAIDs on
platelet thromboxane production by measuring plasma TXB2 levels whereas, in our
study, we utilized urinary 11-dTXB2 as an indicator of platelet thromboxane production.
In contrast to Blois and others55, who found that aspirin had little effect on plasma TXB2
levels in dogs, our study documented that aspirin induced a significant and consistent
decrease in urine 11-dTXB2 levels. The results of our study suggest that measurement of
urinary TXB2 metabolites is a much more sensitive indicator of NSAID-induced
inhibition of platelet thromboxane production than is measurement of plasma TXB2
levels, a finding that is supported by several other studies that conclude that urinary
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TXB2 metabolites are a more reliable indicator of the effects of NSAIDS, and less prone
to sampling artifacts.13,56,57,58,59,60 TXB2 is metabolized at the tissue level into 11dehydro-thromboxane B2, which is then excreted in urine. The 11-dehydro-thromboxane
B2 assays are therefore not subject to sampling artifact related to in-vitro platelet
activation.61,62 Brainard and others27 evaluated the effects of 10 days of oral aspirin
(dosed at 5 mg/kg twice daily, half the dose used in our study), carprofen, deracoxib and
meloxicam on platelet function in 8 dogs with osteoarthritis, and concluded that the more
COX-2 selective NSAIDs had minimal and variable effects on most measures of
hemostasis, though platelet aggregometry was significantly impaired in dogs receiving
aspirin and carprofen. However, the panel of tests used by Brainard and others27, which
consisted of platelet TXB2, plasma TXB2, and 6-keto PGF1α, platelet aggregometry using
collagen and ADP as agonists, and thromboelastography (a method of clot analysis
comparable to viscoelastometry), lacked several of the more sensitive indicators of
NSAID-induced platelet dysfunction such as urinary TXB2 metabolites and utilization of
epinephrine as a platelet agonist. In summary, the results of our study suggest that PFA100® analysis using collagen/EPI cartridges and measurement of urinary 11-dTXB2 may
be more sensitive measures of NSAID-induced platelet dysfunction in dogs than many of
the tests utilized in those previous studies that reported that aspirin and other NSAIDs
had a lesser impact on platelet function.
Viscoelastometry via SonoClot® analyzer has been widely used in human medicine,
including utilization in a number of disease conditions to predict hemorrhage,63,64,65 and
has become particularly important in cardiac surgery.66,67,68,69,70 Viscoelastometry is
considered a quick and simple method of evaluating clotting abnormalities in both
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primary and secondary hemostasis, and can be performed intraoperatively or bedside.
The viscoelastometric signature curve can be evaluated visually or via computergenerated algorithms to determine the source of the abnormality based on changes in
curve shape. General platelet function is believed to be represented by the time to peak.71
Platelet function is also thought to correspond with the shape of the peak, with more
active platelets resulting in a sharper peak.72 There are, however, well documented
limitations to the use of viscoelastometry to evaluate platelet function, including
variability in results related to age, gender, and platelet count,73 and subjectivity
associated with visual curve evaluation. In addition, viscoelastometry has been proven to
be ineffective in detecting aspirin-induced platelet dysfunction in humans.74 Our study is
one of the first to investigate the use of SonoClot® viscoelastometry in veterinary
medicine. Although the validity of viscoelastometry for assessing platelet function in
dogs has not been established, we chose to use the SonoClot® based on its acceptance in
human medicine for the detection of platelet abnormalities. As has been documented in
people, no viscoelastometreic abnormalities were detected after administration of aspirin
to the dogs in our study. However, it is interesting that the SonoClot® ACT was
prolonged after treatment with carprofen 4.4 mg/kg PO q 24 h, and that both carprofen
dosing regimens resulted in a faster CR. While these SonoClot®values are not thought to
reflect platelet function, platelets do provide procoagulant factors, so altered platelet
function could, in theory, affect all aspect of viscoelastometry, including ACT and CR.
In dogs, the newer so-called ‘COX-2 selective’ NSAIDS are in fact not completely
selective for inhibition of COX-2 alone.8,11,12,16,75 The degree of COX-2 selectivity varies
among the newer NSAIDS, with many also having some degree of documented COX-1
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inhibition.11 Since aspirin is known to impair platelet function via inhibition of platelet
COX-1, it would seem likely that the more a newer NSAID inhibits COX-1, the more
likely it is to also impair platelet function. Carprofen, for example, was thought to have
little to no effect on platelet function since it was believed to spare COX-1 activity,26
however the degree of carprofen COX-2 selectivity has not been definitively established.
While one study reported that the potency of carprofen for COX-2 was more than 100fold greater than for COX-1 in dogs,76 another study reported carprofen to be only 1.75
times more selective for COX-2 than COX-1.11 Meloxicam reportedly inhibits canine
COX-2 activity 12 times more effectively than COX-1 activity.11 Since even very low
doses of aspirin are known to impair platelet function in many people via inhibition of
platelet COX-1, it is possible that even if a newer NSAID is responsible for only a small
amount of COX-1 inhibition compared to a relatively much greater COX-2 inhibition,
that small degree of COX-1 inhibition may be enough to significantly impair platelet
function. Our study certainly strongly suggests that all of the newer NSAIDs that we
evaluated have the potential to significantly impair platelet function in individual dogs.
While the results of our study may appear at first glance to contradict the findings of
other recent and superficially similar studies, a close examination of the individual
studies reveals a tremendous variability in the methodologies employed to evaluate
platelet function. Apparently conflicting findings may therefore be to a large extent due
to the use of measures of platelet function that vary widely in their sensitivity to the
effects of aspirin. However, even when two studies use very comparable drug doses and
hemostatic testing methodologies, conflicting results are occasionally reported. For
example, a previous study by Gaal and others evaluating the effects of carprofen on
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platelet function found no difference in PFA-100® closure times between control and
carprofen-treated dogs with either collagen/EPI or collagen/ADP agonist cartridges,77 a
finding that contrasts with the observation in our study that carprofen significantly
prolongs collagen/EPI PFA-100® closure times. Published studies also describe
conflicting results with regards to the effects of meloxicam on bleeding times. Although
Luna and others21 reported prolonged bleeding times in dogs within 7 days of
administration of meloxicam compared to control dogs, our study and another study by
Mathews and others reported that the administration of meloxicam to dogs did not result
in a prolonged BMBT.28,30
Variability in the platelet responses of the individual dogs in our study to the newer
NSAIDs, and perhaps even apparent discrepancies in the results of different published
studies, may potentially be explained by dog-to-dog variability in NSAID responsiveness.
In our study, it was certainly interesting that while all dogs responded to standard antiinflammatory doses of aspirin in a predictable fashion (particularly by prolongation of
PFA-100® collagen/EPI closure times and decreased levels of urine 11-dTXB2),
individual dog responses to the other newer NSAIDs were much more variable. This
variable responsiveness to the newer NSAIDS may be comparable to the variable
responsiveness to low dose aspirin that is well documented in people. In humans, while
high doses of aspirin typically have predictable effects on platelet function via inhibition
of COX-1, platelet responsiveness to low dose aspirin varies widely. Although many
possible etiologies for this variability have been investigated, the mechanism or
mechanisms by which some patients are ‘resistant’ to low dose aspirin remain unknown.
16,48,75

Potentially, the mechanism in dogs that confers variable platelet responsiveness to
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the newer NSAIDS despite a predictable responsiveness to anti-inflammatory doses of
aspirin may be comparable to the mechanism that causes aspirin resistance in people.
In conclusion, aspirin and all of the newer more COX-2 selective NSAIDS evaluated
in our study caused significantly prolonged PFA-100® closure times measured using
collagen/EPI cartridges, indicating NSAID-induced platelet dysfunction. When evaluated
with collagen/ADP cartridges, however, there was no change in PFA-100® closure time,
even with aspirin, confirming that NSAID-induced platelet dysfunction cannot be
accurately assessed using collagen/ADP cartridges. Significant decreases in urinary 11dTXB2 after treatment with aspirin also confirmed aspirin-induced platelet dysfunction,
and although the decrease in 11-dTXB2 did not reach statistical significance, there was a
consistent drop below baseline for all drugs. Failure of the SonoClot® to demonstrate
platelet dysfunction after treatment with aspirin suggests that, as in humans, this
methodology is not appropriate for the detection of aspirin-induced platelet dysfunction
in dogs. Although our study also revealed a prolonged ACT and faster CR after
treatment with carprofen, this result was somewhat unexpected, and should be further
investigated before conclusions are drawn. Our study demonstrated that oral
administration of the commonly used COX-2 selective NSAIDS at standard doses
resulted in significantly decreased platelet function. While we did not undertake to
demonstrate a correlation between the results of laboratory findings and clinical bleeding,
based on the results of our study, hemostatic evaluation of surgical patients known to be
exposed to NSAIDS may be warranted in order to predict and potentially reduce the
incidence of perioperative hemorrhage. Caution may be advised in the administration of
these drugs prior to surgery, particularly in the presence of other risk factors for bleeding.
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e. PFA Collagen/ADP Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
f. PFA Collagen/EPI Test Cartridge, Siemens Healthcare Diagnostics, Duluth, GA
g. SonACT® Kit, Sienco, Inc, Arvada, Colorado
h. Signature ViewerTM Program, Sienco, Inc, Arvada, Colorado
i. ACE Alera® Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell, NJ
j. Triplett Bleeding Time Device®, Helena Laboratories Corp, Beaumont, TX
k. HemoHeel®, Helena Laboratories Corp, Beaumont, TX
l. Aspirin, Major Pharmaceuticals, Livonia, MI
m. Rimadyl, Pfizer Animal Health, NY, NY
n. Metacam suspension (0.5%), Boehringer Ingelheim Vetmedica, St Joseph, MO
o. Deramaxx, Novartis Animal Health, Greensboro, NC
p. SAS for Windows version 9.2, SAS Institute, Cary, NC, 2008
q. Sucralfate, Teva Pharmaceuticals, Sellersvillle, PA
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CHAPTER III
SUMMARY AND CONCLUSIONS

The goal of this project was to investigate the effects of commonly used COX-2
selective NSAIDS on platelet function in the dog. This study found that all of the COX-2
selective NSAIDS evaluated significantly affected platelet function. This finding is
noteworthy because these more selective NSAIDS were developed to help reduce the side
effects caused by COX-1 inhibition, including alterations in platelet function.
Two recently published studies reported different results on the effects of COX-2
selective NSAIDS on platelet function in dogs.27,55 These studies evaluated a similar
number of dogs but used different measurements of platelet function than used in our
study. The study by Blois utilized the PFA-100® collagen/ADP cartridges, but not the
collagen/EPI cartridges, which is likely the reason for their lack of detecting changes in
platelet function. The study by Brainard assessed platelet function by using platelet
aggregation assays, thromboelastography, and measurement of lipopolysaccharidestimulated prostaglandin E2, platelet thromboxane B2 (TXB2), and free serum TXB2 and
6-keto-prostaglandin F(PGF)-1α concentrations. Platelet aggregation decreased after
treatment with aspirin and carprofen, and clot strength decreased after treatment with
carprofen and increased with deracoxib. Testing methods in Brainard’s study were much
different from the methods we used. Testing results may have been affected by the fact
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that the patients were osteoarthritic and client-owned, both of which have the potential to
drastically affect results.
Neither of these published reports assessed platelet function using the PFA-100®
collagen/EPI cartridge or measurement of urinary 11-dTXB2 as used in our study. Both
of these measures of platelet function have proven to be effective methods of determining
platelet dysfunction.13,49,51,56,57,58,59,60 Based on studies in both humans51 and dogs,49
prolongation of PFA-100® collagen/EPI closure time has been found to be a sensitive
indicator of platelet dysfunction due to NSAID administration. In addition, multiple
studies in humans and one in dogs13,56,57,58,59,60 have determined measurements of urinary
TXB2 metabolites to be a more reliable indicator of NSAID affects on platelets than
measures of TXB2 metabolites in other locations, with less sampling artifacts. In our
study, both tests clearly demonstrated their ability to determine platelet dysfunction due
to NSAID administration. Initial evaluation with the PFA-100® collagen/EPI cartridge
after aspirin administration proved it to be a very clear and consistent method of detecting
platelet dysfunction, as there was a significant and obvious alteration in platelet function
with the collagen/EPI cartridge, but not with the collagen/ADP cartridge. Evaluation of
platelet function using the PFA-100® collagen/EPI cartridge after administration of each
of the other NSAIDS in our study also showed a significant alteration in platelet function,
although platelet dysfunction in individual dogs was not as consistent as that seen with
aspirin. While measurement of urinary TXB2 metabolites was significantly decreased
only after aspirin administration, there was a non-significant decline in urinary TXB2
after administration of all the NSAIDS.
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When evaluated using PFA-100® collagen/EPI cartridges, platelet function was more
variable in dogs treated with COX-2 selective NSAIDS than when these same dogs were
treated with aspirin. This may be due to interindividual variability, similar to the
unpredictable response seen in humans to aspirin. The fact that platelet dysfunction,
based on PFA-100® collagen/EPI, after treatment with COX-2 selective NSAIDS was
less pronounced than after aspirin treatment is encouraging, since alterations in platelet
function and other side effects shouldn’t be as severe. However, because treatment with
COX-2 selective NSAIDS resulted in a more variable response than aspirin (as measured
with the PFA-100® collagen/EPI cartridge), severity of potential side effects cannot be
predicted. The cause of this variability is yet undetermined.
The results of the study reported here did not identify a variable response to aspirin
in dogs as has been reported in humans.38,39 All dogs responded quickly and similarly to
aspirin treatment at standard anti-inflammatory doses. However, a larger low dose aspirin
study may need to be performed to detect variations in response to aspirin. It remains
unclear if dogs might have a consistent response to aspirin and a variable response to
COX-2 selective NSAIDS, and additional research is needed for clarification.
Future research should focus on determining if there is a correlation between the
NSAID affects on platelet function described in this study and prolonged bleeding
clinically. The challenge will be to develop an accurate method of objectively quantifying
intraoperative hemorrhage. Methods recently researched to quantify hemorrhage include
measuring irrigation fluid, weighing surgical sponges, using gravimetric measurements,
and quantification using spectrophotometric analysis of hemoglobin content, all of which
were accurate and correlated with amount of blood lost.78 However, gravimetric
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measurements and quantification of hemoglobin content are not practical methods of
quantifying blood loss clinically. BMBT has been weakly but significantly correlated
with intraoperative blood loss78 and is a quick, easy, and inexpensive method of
preoperative evaluation of patients to rule-out major clotting abnormalities. BMBT has
been noted to be significantly prolonged in dogs within 1 day of treatment with aspirin.53
However, in our study, there was no prolongation of BMBT beyond what is considered
normal.
Another interesting direction for future research would be evaluation of platelet
function using the PFA-100 in patients receiving COX-2 selective NSAIDS for an
existing medical condition (i.e. osteoarthritis or acute musculoskeletal trauma). It is not
known if these types of conditions may induce platelet activation and to what degree, if
they specifically alter platelet function in some manner, or if they alter the effects of
COX-2 selective NSAIDS on platelet function.
One of the most exciting possibilities for future research is based on the recent
evidence that COX-2 is expressed by human platelets.79,80 If COX-2 is present in canine
platelets, it may help explain the variable response to different COX-2 selective NSAIDS
in our study. Studies investigating whether canine platelets express COX-2 would be of
great interest and would impact research, drug development, and clinical use of NSAIDS.
It would also encourage interest in the development of pure COX-2 selective NSAIDS
and influence our clinical use of “COX-2 selective” NSAIDS. In fact, a very recent study
has found that when platelets are permeabilized, COX-2 is detected intracellularly.81
There are many more questions to be answered: Why has COX-2 not been previously
detected on canine platelets? Is it only expressed when platelets are activated? What
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percentage of platelets must be activated for clinical effects? What insults would cause
this level of activation – Trauma? Osteoarthritis? Drug administration? What are the
effects of “COX-2 selective” NSAID administration in dogs with other existing
conditions that may or may not induce platelet function?
Continued research of the effects of COX-2 selective NSAIDS on canine platelet
function would not only expand our understanding and knowledge of the topic, but would
also be applicable clinically. More thorough preparation could be made for dogs on these
drugs undergoing surgery, resulting in less risk to the patient and less morbidity.
There are several limitations to our study. Firstly, only eight dogs were evaluated in
a cross-over study design. This number was determined to be the minimum number
needed to evaluate for the presence of aspirin responders and non-responders, and to
insure that minor variations in individual dog measurements would not alter our overall
findings. This number is consistent with common recommendations for pharmacokinetic
studies of this type,82 and is extrapolated from a recent publication27 describing a similar
study in which the same design and animal numbers were used. The crossover design
allowed for the complete evaluation of four different NSAIDS/dosages while utilizing
only 8 dogs. Fortunately, eight dogs was, in our study, sufficient to detect significant
alterations in platelet function with all of the NSAIDS evaluated, although it is possible
that there were not enough dogs to provide sufficient power to detect alterations in
urinary TXB2 levels with the more COX-2 selective NSAIDS.
Another limitation is that both collagen/EPI and collagen/ADP cartridges were not
used at all time points in the study. It could be argued that since closure time for both
collagen/EPI and collagen/ADP cartridges must be evaluated to rule out more severe
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platelet function disorders, both cartridges should have been used at all time points.
However, because there was such a large difference between the two cartridges when
used with the initial aspirin treatment of these dogs, we determined it was unnecessary to
obtain measurements with both cartridges at each time point. In addition, we determined
prior to the study that all of the dogs were free of diseases known to cause platelet and
clotting dysfunction. Also, based on descriptions of the PFA-100®51,83 and previous
studies evaluating its use,84,85 the collagen/ADP cartridge is only beneficial in detecting
disorders of primary hemostasis such as von Willebrand disease and thrombopathia,
while the collagen/EPI cartridge detects aspirin-like defects.
An additional limiting factor may be the use of intact female dogs. Several dogs were
observed to go through heat cycles during the study, which could theoretically alter
platelet count and PCV. However, we measured those values at peak administration of all
drugs with no difference detected from baseline values.
In conclusion, with the expanding use of NSAIDS in veterinary medicine, their
affects on the body, particularly hemostasis, need to be better understood. For many
conditions currently treated with NSAIDS, elective surgical options are available and
even recommended. If it is determined that certain NSAIDS, particularly the more
commonly used COX-2 selective NSAIDS, cause increased intraoperative hemorrhage
due to platelet dysfunction, steps can be taken preoperatively to prevent excessive
surgical hemorrhage and other potentially life-threatening complications that may result.
At this point, based on the results of this study, caution should be exercised when
administering cox-2 selective NSAIDS to dogs, particularly those with other hematologic
abnormalities and those that may need surgery.
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